Osborne Clarke in Amsterdam has advised Breath and existing shareholders Gimv, Sofinnova Partners, Gilde Healthcare and founders on the sale of Breath Therapeutics to Zambon for up to a total of €500 million subject to regulatory and sales milestones with an upfront payment of €140 million.
Breath Therapeutics specializes in advanced and first-in-class inhalation therapies for severe respiratory diseases. Zambon is a multinational pharmaceutical company that focuses on innovation and development with the aim to improve the quality of people's health and patients' lives.
In 2017, Osborne Clarke in Amsterdam also advised Breath Therapeutics on the €43.5 million Series A financing round, co-led by Gimv and Sofinnova Partners and Gilde Healthcare.
Osborne Clarke’s international life science and healthcare sector team has a strong track record of providing highly sophisticated advice to investors and biotech clients on cutting-edge issues, across multiple service lines. They work with blue chip venture capital firms, the biggest pharma and medical devices companies in the market and earlier this year, advised generic pharmaceutical company Actavis UK Limited and Actavis Ireland Limited on its £603m divestment by Teva Pharmaceutical Industries Ltd to Intas Pharmaceuticals Ltd.